ICUI Earnings Date: Nov 5, 2026 (Estimated) — ICU Medical, Inc.
NASDAQ · Healthcare · Medical Instruments & Supplies
Updated
When is ICUI's next earnings date?
ICU Medical, Inc. (ICUI) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.14 on revenue of $552.1M.
How did ICUI do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), ICU Medical, Inc. posted EPS of $2.37 versus the $1.91 estimate, a beat of 30.2%. Revenue was $551.7M against a $533.4M estimate. The stock's 1-day post-earnings move was +10.9%.
How much does ICUI stock move after earnings?
ICUI beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.0% (up or down) in the day after earnings.
About ICU Medical, Inc.
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 1.91 | 2.37 | +30.22% | $551.7M | ✅ Beat | +10.93% | +10.06% | +0.73% |
| 2026-05-07 | Q1 2026 | 1.67 | 1.97 | +17.96% | $530.2M | ✅ Beat | +2.73% | -0.07% | +11.71% |
| 2026-02-19 | Q4 2025 | 1.54 | 1.91 | +24.03% | $540.7M | ✅ Beat | +4.87% | +0.72% | -16.28% |
| 2025-11-06 | Q3 2025 | 1.31 | 2.03 | +54.96% | $537.0M | ✅ Beat | +8.09% | +6.83% | +10.87% |
| 2025-02-27 | Q4 2024 | 1.48 | 2.11 | +42.57% | $629.8M | ✅ Beat | -2.28% | -5.03% | -6.40% |
| 2024-11-12 | Q3 2024 | 1.25 | 1.59 | +27.20% | $589.1M | ✅ Beat | -1.80% | -4.67% | -6.98% |
| 2024-08-07 | Q2 2024 | 1.00 | 1.56 | +56.00% | $596.5M | ✅ Beat | +24.27% | +21.52% | +33.28% |
| 2024-05-07 | Q1 2024 | 0.82 | 0.96 | +17.07% | $566.7M | ✅ Beat | -1.15% | +3.42% | +6.46% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $96.5M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Equipment revenue | 79.4% | $76.6M | +152.3% | — | — | $30.4M | $51.6M |
| Software revenue | 19.3% | $18.6M | +652.4% | — | — | $2.5M | $4.3M |
| Other deferred revenue | 1.4% | $1.3M | +237.7% | — | — | $390K | $646K |
By region
Q2 FY26 · $551.7M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 63.4% | $349.9M | +4.3% | $413.3M | $388.2M | $335.4M | $307.1M |
| EMEA | 17.2% | $95.1M | -4.0% | $98.1M | $95.7M | $99.1M | $115.1M |
| Asia Pacific | 10.1% | $55.6M | -4.7% | $58.6M | $59.4M | $58.4M | $57.5M |
| Other foreign countries | 9.3% | $51.1M | -8.7% | $58.9M | $61.4M | $56.0M | $57.3M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.